Pakistan Stock Exchange on Wednesday informed investors that BF Biosciences Limited has applied for listing on the Main Board of PSX.
The total issue size of the Initial Public Offering comprises 25 million ordinary shares having a par value of Rs. 3/- each using the Book Building Method at a Floor Price of Rs. 55/- per share. Arif Habib Limited is the Lead Manager of the Issue.
Under Circular No. 16 of 2023 dated November 08, 2023, notified by the Securities & Exchange Commission of Pakistan (SECP), the Draft Prospectus of the Company is hereby placed on the PSX Website under the caption of “Public Comments on Draft Prospectus of BF Biosciences Limited”.
Details about the issue can be reviewed through the attached draft of the company’s prospectus.
BF Bioscience is a pioneering joint venture between Ferozsons Laboratories Limited and the Bagó Group of Argentina was founded in 2006 as Pakistan first CGMP biotech formulation company.
Its primary focus is on advance healthcare solutions for hepatology, oncology, and other established molecular products. The company has exclusive partnership with Gilead Sciences Inc. for their branded products in the areas of HBV, HCV, and HIV. Furthermore, it has an in-country license to produce authorized generics of Gilead’s HCV products
Editorial & Legal Practice Group
Authored and reviewed by the corporate law and tax litigation practice group at Javid Law Associates. Our team comprises High Court advocates, corporate legal advisors, and authorized tax practitioners across Pakistan.
Advocates High Court & Tax Counsel
Jurisdiction: Pakistan